Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Xuan Ni Tan"'
Autor:
Khai Li Chai, Cameron Wellard, LTP Thao, Naomi Aoki, Elizabeth M Moore, Bradley M Augustson, Akshay Bapat, Hilary Blacklock, Wee J Chng, Rachel Cooke, Cecily J Forsyth, Yeow‐Tee Goh, Nada Hamad, Simon J Harrison, P Joy Ho, Jay Hocking, Ian Kerridge, Jin Seok Kim, Kihyun Kim, Tracy King, Georgia J McCaughan, Peter Mollee, C Orla Morrissey, Nick Murphy, Hang Quach, Xuan Ni Tan, Allison CY Tso, Kimberly SQ Wong, Sung‐Soo Yoon, Andrew Spencer, Erica M Wood, Zoe K McQuilten
Publikováno v:
eJHaem, Vol 5, Iss 4, Pp 690-697 (2024)
Abstract Serious infection is common in patients with multiple myeloma due to immune deficiency from the underlying disease and/or its treatment. Immunoglobulin replacement is one approach to reduce infection risk in these patients. However, few real
Externí odkaz:
https://doaj.org/article/5a24a48b600f4da59acde72c4e4cde39
Publikováno v:
Internal Medicine Journal. 52:1242-1250
Background Several international centres have published their experiences with outpatient autologous stem cell transplantation (ASCT) as treatment of haematological malignancies. Aim In this single-centre retrospective review, we aim to examine the o
Publikováno v:
Pathology. 55:S93
Autor:
Jonathon B. Cohen, Nirav N. Shah, Alvaro J. Alencar, James N. Gerson, Manish R. Patel, Bita Fakhri, Wojciech Jurczak, Xuan Ni Tan, Katharine L. Lewis, Timothy Fenske, Catherine C. Coombs, Ian W. Flinn, David J. Lewis, Steven Le Gouill, M. Lia Palomba, Jennifer A. Woyach, John M. Pagel, Nicole Lamanna, Minal A. Barve, Paolo Ghia, Toby A. Eyre, Pier Luigi Zinzani, Chaitra S. Ujjani, Youngil Koh, Koji Izutsu, Ewa Lech-Maranda, Constantine S. Tam, Suchitra Sundaram, Ming Yin, Binoj Nair, Donald E. Tsai, Minna Balbas, Anthony R. Mato, Chan Y. Cheah, Michael L. Wang
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 22:S394-S395
Covalent BTK inhibitors (BTKi) have transformed the management of mantle cell lymphoma (MCL), but most patients will require additional treatment. Pirtobrutinib is a highly selective, non-covalent (reversible) BTKi that inhibits both wild-type and C4
Autor:
Steven Le Gouill, Nora Ku, Chan Yoon Cheah, Binoj Nair, Jennifer A. Woyach, Minal A. Barve, Timothy S. Fenske, John M. Pagel, Alvaro J. Alencar, M. Lia Palomba, Ian W. Flinn, Catherine C. Coombs, Bita Fakhri, David John Lewis, Nirav N. Shah, Paolo Ghia, Toby A. Eyre, Michael Wang, Donald E. Tsai, James N. Gerson, Anthony R. Mato, Katharine L Lewis, Manish R. Patel, Jonathon B. Cohen, Nicole Lamanna, Ming Yin, Xuan Ni Tan, Wojciech Jurczak
Publikováno v:
Blood. 136:8-10
Background: Covalent BTK inhibitors (BTKi) have transformed the management of MCL, WM, and MZL. Despite the marked efficacy of covalent BTKi, treatment failure can occur through the development of resistance and discontinuation for adverse events. Co
Autor:
Jonathon B. Cohen, Nirav N. Shah, Alvaro J. Alencar, James N. Gerson, Manish R. Patel, Bita Fakhri, Wojciech Jurczak, Xuan Ni Tan, Katharine L. Lewis, Timothy Fenske, Catherine C. Coombs, Ian W. Flinn, David J. Lewis, Steven Le Gouill, M. Lia Palomba, Jennifer A. Woyach, John M. Pagel, Nicole Lamanna, Minal A. Barve, Paolo Ghia, Toby A. Eyre, Pier Luigi Zinzani, Chaitra S. Ujjani, Youngil Koh, Koji Izutsu, Ewa Lech-Maranda, Constantine S. Tam, Suchitra Sundaram, Ming Yin, Binoj Nair, Donald E. Tsai, Minna Balbas, Anthony R. Mato, Chan Y. Cheah, Michael L. Wang
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 22:S175
Autor:
Jonathon B. Cohen, Nirav N. Shah, Alvaro J. Alencar, James N. Gerson, Manish R. Patel, Bita Fakhri, Wojciech Jurczak, Xuan Ni Tan, Katharine L. Lewis, Timothy Fenske, Catherine C. Coombs, Ian W. Flinn, David J. Lewis, Steven Le Gouill, M. Lia Palomba, Jennifer A. Woyach, John M. Pagel, Nicole Lamanna, Minal A. Barve, Paolo Ghia, Toby A. Eyre, Pier Luigi Zinzani, Chaitra S. Ujjani, Youngil Koh, Koji Izutsu, Ewa Lech-Maranda, Constantine S. Tam, Suchitra Sundaram, Ming Yin, Binoj Nair, Donald E. Tsai, Minna Balbas, Anthony R. Mato, Chan Y. Cheah, Michael L. Wang
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 22:S118
Autor:
Ming Yin, Edward Y. Zhu, Justin Taylor, Michael Wang, Anthony R. Mato, Matthew S. Davids, Nora Ku, Lindsey E. Roeker, Ian W. Flinn, Jennifer A. Woyach, Johan Wallin, Nicole Lamanna, Timothy S. Fenske, Donald E. Tsai, Steven Le Gouill, Suchitra Sundaram, David J. Lewis, John M. Pagel, Toby A. Eyre, Catherine C. Coombs, Stephen J. Schuster, Kevin Ebata, Xuan Ni Tan, Manish R. Patel, Jonathon B. Cohen, Narasimha Marella, Katharine L Lewis, Chan Yoon Cheah, Omar Abdel-Wahab, Bita Fakhri, Binoj Nair, Bryone J. Kuss, M. Lia Palomba, Constantine S. Tam, Alvaro J. Alencar, Wojciech Jurczak, Nirav N. Shah, James N. Gerson, Jennifer R. Brown, Paolo Ghia, Ewa Lech-Marańda, Minal A Barve, Jessica A. Chen, William G. Wierda
Publikováno v:
The Lancet
The Lancet, 2021, 397 (10277), pp.892-901. ⟨10.1016/S0140-6736(21)00224-5⟩
Lancet
Lancet, Elsevier, 2021, 397 (10277), pp.892-901. ⟨10.1016/S0140-6736(21)00224-5⟩
The Lancet, 2021, 397 (10277), pp.892-901. ⟨10.1016/S0140-6736(21)00224-5⟩
Lancet
Lancet, Elsevier, 2021, 397 (10277), pp.892-901. ⟨10.1016/S0140-6736(21)00224-5⟩
International audience; Background: Covalent Bruton's tyrosine kinase (BTK) inhibitors are efficacious in multiple B-cell malignancies, but patients discontinue these agents due to resistance and intolerance. We evaluated the safety and efficacy of p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ec4facff70af93a082c78985f5284f1e
https://ruj.uj.edu.pl/xmlui/handle/item/290422
https://ruj.uj.edu.pl/xmlui/handle/item/290422
Autor:
Jay Hocking, Erica M. Wood, Tracy King, Phoebe Joy Ho, Orla Morrissey, Xuan Ni Tan, Khai Li Chai, Akshay Bapat, Nicholas E. Murphy, Elizabeth Moore, Bradley Augustson, Andrew Spencer, Nada Hamad, Hilary Blacklock, Rachel Elizabeth Cooke, Cecily Forsyth, Georgia McCaughan, Cameron Wellard, Hang Quach, Ian Kerridge, Kimberly Wong, Simon J. Harrison, Zoe McQuilten, Peter Mollee
Publikováno v:
Blood. 138:4757-4757
Introduction Serious infection is common in patients with multiple myeloma (MM), and associated with major morbidity and mortality. Immunoglobulin (Ig) replacement is frequently used to reduce frequency and severity of infections, however evidence is
Autor:
Manish R. Patel, Chan Yoon Cheah, Ian W. Flinn, Jennifer A. Woyach, Nirav N. Shah, Jonathon B. Cohen, Binoj Nair, Timothy S. Fenske, Minal A. Barve, Suchitra Sundaram, M. Lia Palomba, Michael Wang, Constantine S. Tam, Toby A. Eyre, Ewa Lech-Marańda, John M. Pagel, Nicole Lamanna, Anthony R. Mato, Minna Balbas, Donald E. Tsai, Wojciech Jurczak, Koji Izutsu, Catherine C. Coombs, Paolo Ghia, Katharine L Lewis, Alvaro J. Alencar, David J. Lewis, Youngil Koh, Ming Yin, Chaitra S. Ujjani, Steven Le Gouill, Xuan Ni Tan, Pier Luigi Zinzani, Bita Fakhri, James N. Gerson
Publikováno v:
Blood. 138:381-381
Background: Covalent BTK inhibitors (BTKi) have transformed the management of mantle cell lymphoma (MCL), but these treatments are not curative and the majority of patients (pts) will require additional treatment. Covalent BTKi share pharmacologic li